Abstracts Archive - Page 951 of 2425 - ACR Meeting Abstracts

Abstract Number: 2893 • 2019 ACR/ARP Annual Meeting
Long-term Clinical and Economic Benefits of a Short-term Physical Activity Intervention Among Inactive Knee Osteoarthritis Patients in US: A Model-based Evaluation
Genevieve Silva¹, James Sullivan ², Jeffrey Katz ³, Stephen Messier ⁴ and Elena Losina ⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital/Harvard Medical School, Boston, ⁴Wake Forest University, Winston Salem, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: The United States (US) knee osteoarthritis (OA) population has low levels of physical activity (PA), despite its well-defined health benefits. Interventions to promote PA…
Abstract Number: 2894 • 2019 ACR/ARP Annual Meeting
CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity
Evan Der ¹, Ting Zhang ², Chi Chiu Mok ³, Ramesh Saxena ⁴, Krishna R. Polu ⁵, Chandra Mohan ⁶ and Chaim Putterman⁷, ¹Albert Einstein College of Medicine, New York, ²Biomedical Engineering, University of Houston, Houston, TX, ³Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ⁴University of Texas South Western, Dallas, TX, ⁵Equillium, San Diego, CA, ⁶University of Houston, Houston, ⁷Albert Einstein College of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in Systemic lupus erythematosus (SLE) patients. However, the pathogenesis of renal disease in…
Abstract Number: 2895 • 2019 ACR/ARP Annual Meeting
Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis
Anne Troldborg¹, Anne Voss ², Søren Werner Karlsjov Hansen ³, Jens Christian Jensenius ⁴, Kristian Stengaard-Pedersen ⁵ and Steffen Thiel ⁶, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Odense University Hospital, Department of Rheumatology, Odense, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Aarhus University, department of biomedicine, Aarhus, Denmark, ⁵Department of Rheumatology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark, Aarhus, Denmark
Background/Purpose: Nephritis is a severe manifestation of systemic lupus erythematosus (SLE) that develops in 30 to 50 percent of the patients. At the time of…
Abstract Number: 2896 • 2019 ACR/ARP Annual Meeting
The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?
Chary Lopez-Pedrera¹, Alejandro Ibañez-Costa ¹, Mª Ángeles Aguirre-Zamorano ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ¹, Maria Luque-Tevar ¹, Maria del Carmen Abalos-Aguilera ¹, Ivan Arias de la Rosa ⁴, Nuria Barbarroja ⁵, Mario Espinosa ⁶, Eduardo Collantes-Estevez ⁴, Justo Castaño ⁷, Raúl Luque ⁷ and Carlos Perez-Sanchez ⁸, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁶UGC de Nefrología. Hospital Universitario Reina Sofía, Cordoba, Spain, ⁷Maimónides Institute for Biomedical Research at Córdoba, Cordoba, Spain, ⁸Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The aim of this study was to evaluate whether alterations in the splicing machinery of immune cells could influence the development and activity of…
Abstract Number: 2897 • 2019 ACR/ARP Annual Meeting
Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials
Majid Zeidi ¹, Kristen Chen ¹, Krisha Desai ¹, Hee Joo Kim ², Srita Chakka ³, Rachel Lim ⁴ and Victoria Werth¹, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA andDepartment of Dermatology, University of Pennsylvania, Philadelphia, PA, USA and Department of Dermatology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea, Republic of (South), Philadelphia, ³Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ⁴Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA, Philadelphia
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an autoimmune disease with various subsets and clinical manifestations. T lymphocytes are the predominant cell type found in lesional…
Abstract Number: 2898 • 2019 ACR/ARP Annual Meeting
Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis
Hemant Suryawanshi¹, Robert Clancy ², Evan Der ³, Peter Izmirly ², H Michael Belmont ⁴, Chaim Putterman ⁵, Jill Buyon ² and Thomas Tuschl ¹, ¹Rockefeller Research Laboratories, New York, ²NYU School of Medicine, New York, ³Albert Einstein College of Medicine, New York, ⁴NYU Langone Health, New York, NY, ⁵Albert Einstein College of Medicine, New York, NY
Background/Purpose: The impact of renal injury in lupus nephritis (LN) is widespread with consequences to resident cells in other tissue beds, even non-lesional, non-sun exposed…
Abstract Number: 2899 • 2019 ACR/ARP Annual Meeting
Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation
Kathryn Kingsmore¹, Sarah Heuer ¹, Erika Hubbard ¹, Michelle Catalina ², Prathyusha Bachali ², Peter Lipsky ³ and Amrie Grammer ¹, ¹AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) affects various organs and tissues, but whether pathologic processes in each organ are distinct or whether dysregulated molecular functions are…
Abstract Number: 2900 • 2019 ACR/ARP Annual Meeting
Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20
Sarah Blackstone¹, Daniella Schwartz ¹, Natalia Sampaio Moura ¹, Deborah Stone ¹, Meryl Waldman ¹, Patrycja Hoffmann ¹, Anne Jones ¹, Tina Romeo ¹, Karyl Barron ¹, Joshua Milner ¹, Daniel Kastner ¹ and Amanda Ombrello ¹, ¹National Institutes of Health, Bethesda, MD
Background/Purpose: The protein A20, encoded by TNFAIP3, represses signaling upstream of the inflammatory transcription factor nuclear factor (NF)-kB by regulating ubiquitination. Heterozygous loss-of-function mutations in…
Abstract Number: 2901 • 2019 ACR/ARP Annual Meeting
Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-center Experience
Serdal Ugurlu ¹, Bugra Han Egeli², Bilgesu Ergezen ³, Oguzhan Selvi ³ and Huri Ozdogan ³, ¹Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, istanbul, Turkey, ²İstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanul University-Cerrahpasa, istanbul, Turkey
Background/Purpose: The main goal of Familial Mediterranean Fever (FMF) treatment is to prevent attacks and subclinical inflammation. Mainstay of treatment is colchicine; however, 5-10% of…
Abstract Number: 2902 • 2019 ACR/ARP Annual Meeting
The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease
Christopher Mesa¹, Snehaja Yadlapati ¹ and Myriam Guevara ², ¹Louisiana State University Health Science Center, New Orleans, LA, ²Louisiana State University School of Medicine, New Orleans
Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such…
Abstract Number: 2903 • 2019 ACR/ARP Annual Meeting
Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab – Long-Term Follow-up Data Documents Sustained Safety and Remission
Jasmin Kuemmerle-Deschner¹, Norbert Blank ², Michael Borte ³, Ivan Foeldvari ⁴, Gerd Horneff ⁵, Prasad Thomas Oommen ⁶, Catharina Schuetz ⁷, Frank Weller-Heinemann ⁸, Julia Weber-Arden ⁹ and Tilmann Kallinich ¹⁰, ¹University Hospital Tuebingen, Pediatric Department, Tuebingen, Germany, ²Rheumatology, University Hospital Heidelberg, Germany, Heidelberg, Germany, ³3ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Duesseldorrf, Germany, ⁷Department of Pediatrics, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany, Dreaden, Germany, ⁸Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ⁹Novartis Pharma GmbH Germany, Nuremberg, Germany, ¹⁰Charite, Berlin, Germany
Background/Purpose: Targeting the interleukin(IL)-1 pathway with anti-IL-1 drugs is a treatment option in patients with autoinflammatory diseases like monogenic periodic fever syndromes. The study aims…
Abstract Number: 2904 • 2019 ACR/ARP Annual Meeting
Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD
Julia Sun¹, Charles Oshinsky ², Nicole Garcia ³, Iazsmin Ventura ³, Renea Jablonski ⁴, Rekha Vij ⁴, James Curran ⁵, Mary Strek ⁴ and Ayodeji Adegunsoye ⁴, ¹University of Chicago Department of Internal Medicine, Chicago, ²University of Chicago, Department of Internal Medicine, Chicago, ³University of Chicago, Chicago, ⁴University of Chicago, Department of Pulmonary and Critical Care, Chicago, ⁵University of Chicago, Department of Rheumatology, Chicago
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality and carries significant morbidity in connective tissue disease (CTD). Corticosteroids are often used as…
Abstract Number: 2905 • 2019 ACR/ARP Annual Meeting
Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
Allan Klein ¹, David Lin ², Paul Cremer ¹, Saifullah Nasir ³, Sharon Crugnale ⁴, Larisa Collins ⁴, Fang Fang ⁴, Anna Beutler ⁴ and John F Paolini⁴, ¹Cleveland Clinic, Cleveland, OH, ²Minneapolis Heart Institute - Minneapolis, Minneapolis, MN, ³Stat! Cardiologist, Chicago, IL, ⁴Kiniksa Pharmaceuticals Corp, lexington, MA
Background/Purpose: Recurrent pericarditis (RP) is characterized by the recurrence of pericarditis signs and symptoms after a symptom-free period of ≥4 to 6 weeks and affects…
Abstract Number: 2906 • 2019 ACR/ARP Annual Meeting
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Elise van Mulligen¹, Angelique Weel ², Martijn Kuijper ², Mieke Hazes ¹, Annette van der Helm-van Mil ³ and Pascal de Jong ¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: In rheumatoid arthritis (RA) disease outcomes have improved enormously in the last decades. Due to early initiation of therapy, a treat-to-target approach and a…
Abstract Number: 2907 • 2019 ACR/ARP Annual Meeting
Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
Roy Fleischmann¹, Mark Genovese ², Ricardo Blanco ³, Stephen Hall ⁴, Glen Thomson ⁵, Filip Van den Bosch ⁶, Cristiano A. Zerbini ⁷, Jose Jeffrey Enejosa ⁸, Yihan Li ⁹, Ryan DeMasi ⁹ and In-Ho Song ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University, Stanford, CA, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁴Monash University and Emeritus Research, Melbourne, Australia, ⁵CIADS Research, Winnipeg, Canada, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁸AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁹AbbVie Inc., North Chicago, IL
Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].